Needham Reiterates Buy Rating on CARL
Analyst David Saxon of Needham maintains a buy rating on CARL with a $17 target, a 63.78% upside from the current price.
Key Points
- Needham's David Saxon reiterated a buy rating on CARL with a $17 price target on July 1, 2026.
- Needham's $17 price target implies 63.78% upside from Carlsmed, Inc.'s ($CARL) current $10.38 share price.
- Shares of CARL traded near $10.38 on Wednesday, reflecting ongoing interest from investors.
- Institutional activity shows Janus Henderson grew its CARL holdings by 86,834 shares, now worth about $11.1 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, Needham analyst David Saxon reiterated his buy rating on CARL, setting a price target of $17. This decision underscores continued confidence in the stock's potential growth.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in CARL
Institutional investors have shown varied interest in CARL recently. Orbimed Advisors LLC held steady with 1,252,600 shares valued at approximately $11.3 million. Janus Henderson Group PLC increased its position by 86,834 shares, bringing its total to 1,227,452 shares worth about $11.1 million. Parkman Healthcare Partners LLC opened a new position with 521,123 shares valued at $4.7 million. BlackRock, Inc. added 19,418 shares, ending with 446,892 shares valued at roughly $4 million. Schonfeld Strategic Advisors LLC also initiated a new stake with 283,180 shares, valued at $2.6 million.
Carlsmed, Inc. Stock Down 38.5%
Shares of CARL traded near $10.38 on Wednesday. Despite lacking details on market cap and P/E ratios, the stock's activity reflects investor interest. The presence of notable institutional investors suggests confidence in its future performance.
$CARL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On July 1, 2026, Needham's David Saxon reiterated a buy rating on CARL with a $17 price target. BTIG also reiterated a buy rating on May 6, 2026, with a target of $23. Truist Securities maintained its buy rating on April 15, 2026, setting a target of $18, while Goldman Sachs maintained a buy rating with a $17 target on April 9, 2026. The consensus among analysts remains positive, with a general buy recommendation.
Bottom Line
Needham's reiteration of a buy rating for CARL, along with a $17 price target, highlights ongoing optimism from analysts. Institutional investors' varied activity further suggests a mixed but generally positive outlook. As always, 13F filings and analyst ratings provide historical perspectives and are not indicative of future performance.
Get Carlsmed, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CARL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.